After Johnson & Johnson reversed its decision last year regarding the acquisition of Tryvio (aprocitentan) in 2017, the original manufacturer of the hypertension treatment drug, Idorsia Pharmaceuticals has successfully guided the drug through the FDA approval process.
The company stated that Tryvio, its endothelin receptor antagonist, has received FDA approval. Tryvio is an oral hypertension medication designed to be taken once daily in conjunction with other antihypertensive medications. It is intended for hypertension treatment in adults who haven’t achieved sufficient control with other hypertension medications, aiming to lower blood pressure levels.
It h...
